A.S. KURAKINA, N.A. SCHELCHKOVA, I.V. MUKHINA, V.N. GRIGOREVA

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation, Nizhny Novgorod

  Contact details:

Kurakina A.S. — graduate student of the Department of Neurology, Neurosurgery and Medical Genetics

Address: 10/1 Minina i Pozharkogo Sq., Nizhny Novgorod, Russian Federation, 603005, tel.: +7-910-796-69-92, e-mail: nansy.trifonova@mail.ru

 The purpose of the study was to determine the possibility of diagnosing postoperative cerebral complications by determining the neuron-specific enolase in the blood plasma of patients with meningiomas.

Material and methods. The study involved 70 patients with meningiomas and 62 healthy people. Upon admission to the hospital (T0), all patients underwent clinical and neurological examination and determination of neuron-specific enolase (NSE) in the blood plasma by enzyme-linked immunosorbent assay. Clinical and neuroimaging diagnostics of early postoperative cerebral complications, assessment of their severity, determination of NSE level 5–6 days after tumor removal (T1) were additionally performed for patients with meningiomas.

Results. The average NSE level in patients with meningiomas (3 (2,1; 6,2) ng/ml) did not statistically significantly differ from its level in healthy individuals (4,1 (2,3; 7) ng/ml). The severity of neurological symptoms and the intensity of headaches in patients with meningiomas were statistically significantly positively associated with plasma NSE levels (r = 0,35, p = 0,01 and r = 0,26, p = 0,03 respectively). In patients with moderate and severe early postoperative complications, the NSE level on the 5–6^th day after surgical treatment (T1) was statistically significantly increased (p = 0,004). In patients with mild complications or the absence of complications, NSE concentrations did not differ statistically significantly between T0 and T1. ROC analysis allowed us to take the concentration of NSE in the blood as 9,8 ng/ml for a diagnostically significant separation point. Verification of moderate and severe cerebral complications after removal of meningioma by the NSE content in the blood has a sensitivity of 71% and a specificity — of 87%.

Conclusion. For the purpose of early diagnosis of cerebral complications in patients after removal of meningioma, it is advisable to determine the level of NSE in the blood.

Key words: meningiomas, neuron-specific enolase, diagnosis of early postoperative complications.

(For citation: Kurakina A.S., Schelchkova N.A., Mukhina I.V., Grigoreva V.N. Determination of the content of neurospecific enolase in blood for diagnosis of early postoperative cerebral complications after removal of meningioma. Practical Medicine. 2019. Vol. 17, № 7, P. 149-153)

REFERENCES

1. Krylov V.V. Lektsii po neyrokhirurgii [Lectures on neurosurgery]. Moscow: KMK, 2008. 280 p.
2. Karakhan V.B., Aleshin V.A., Belov D.M. et al. Are oncological principles necessary in the surgery of meningiomas? Block removal of a giant meningioma of the frontal region on the right with extra intracranial spread: description of the clinical case. Opukholi golovy i shei, 2014, no. 1, pp. 50–54 (in Russ.).
3. Bejjani G.K., Sekhar L.N., Yost A.M. et al. Vasospasm after cranial base tumor resection: pathogenesis, diagnosis, and therapy. Surg Neurol, 1999, vol. 52 (6), pp. 577–583.
4. Nittby H.R., Maltes A.,Stahl N. Early postoperative haematomas in neurosurgery. Acta Neurochir (Wien), 2016, Vol. 158 (5), P. 837–846.
5. Ehresman J.S., Garzon-Muvdi T., Rogers D. et al. Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma. J Neurol Surg B Skull Base, 2019, vol. 80 (1), pp. 59–66.
6. Grishanova T.G., Budaev A.V., Grigor’ev E.V., Vavin G.V. Pathogenesis, markers of brain damage and integral assessments of the condition of patients with severe combined injuries. Meditsina v Kuzbasse, 2010, no. 3, pp. 3–8 (in Russ.).
7. Akberov R.F., Yaminov I.Kh., Safiullin R.R., Puzakin E.V. Diagnosis of brain tumors: the possibilities of magnetic resonance imaging. Prakticheskaya meditsina, 2011, vol. 1, no. 49, pp. 54–57 (in Russ.).
8. Balandina A.V., Kapishnikov A.V., Kozlov S.V. Possibilities of magnetic resonance and perfusion computed tomography in the diagnosis of glial brain tumors. Kazanskiy meditsinskiy zhurnal, 2015, vol. 96, no. 6, pp. 949–951 (in Russ.).
9. Morgun A.V., Ovcharenko N.V., Taranushenko T.E. et al. Markers of apoptosis and neurospecific proteins in the diagnosis of perinatal lesions of the central nervous system in newborns. Sibirskoe meditsinskoe obozrenie, 2013, no. 3, pp. 3–11 (in Russ.).
10. Khrapov Yu.V., Poroyskiy S.V. The role of biomarkers of damage to brain matter in the diagnosis, evaluation of treatment effectiveness and prediction of outcomes of severe traumatic brain injury. Volgogradskiy nauchno-meditsinskiy zhurnal, 2013, no. 3, pp. 10–20 (in Russ.).
11. Vedunova M.V., Terent’eva K.A., Shchelchkova N.A. et al. Diagnostic value of determining the concentration of neurotrophic factors and neuron-specific enolase in the blood of newborns with central nervous system disorders. STM, 2015, vol. 7, no. 2, pp. 25–32 (in Russ.).
12. Serikova I.Yu., Vorob’eva E.N., Shumakher G.I. Laboratory markers of the late effects of perinatal CNS damage in adolescents. Journal of Siberian Medical Sciences, 2013, no. 2, pp. 1–6 (in Russ.).
13. Piast M., Kustrzeba-Wójcicka I., Matusiewicz M., Banaś T. Molecular evolution of enolase. Acta biochimica Polonica, 2005, vol. 52 (2), pp. 507–513.
14. Blinov D.V. BBB permeability assessment for neurospecific enolase in perinatal hypoxic-ischemic damage to the central nervous system. Akusherstvo, ginekologiya i reproduktsiya, 2013, vol. 7, no. 4, pp. 15–19 (in Russ.).
15. Cheng F., Yuan Q., Yang J. et al. Prognostic Value of Serum Neuron-Specific Enolase in Traumatic Brain Injury. PLoS One, 2014, vol. 9 (9), available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154726/
16. Sosnovskiy E.A., Puras Yu.V., Talypov A.E. Biochemical markers of traumatic brain injury. Neyrokhirurgiya, 2014, no. 2, pp. 83–91 (in Russ.).
17. Bohmer A.E., Oses J.P., Schmidt A.P. et al. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery, 2011, vol. 68 (6), pp. 1624–1630.
18. González-García S., González-Quevedo A., Fernández-Concepción O. et al. Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients. Clinical Biochemistry, 2012, vol. 45 (16), pp. 1302–1307.
19. Singh H.V., Pandey A., Shrivastava A.K. et al. Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. Clinica Chimica Acta, 2013, vol. 419, pp. 136–138.
20. Kadashev B.A. Adenomy gipofiza: klinika, diagnostika, lechenie [Pituitary adenomas: clinic, diagnosis, treatment]. Moscow: Triada, 2007. 367 p.
21. Grigor’ev A.Yu., Azizyan V.N., Ivashchenko O.V. et al. Results of surgical treatment of somatotropic pituitary adenomas. Endokrinnaya khirurgiya, 2008, vol. 2, no. 1, pp. 6–9 (in Russ.).
22. Yamamoto J., Takahashi M., Idei M. et al. Clinical features and surgical management of intracranial meningiomas in the elderly. Oncol Lett, 2017, vol.14 (1), rr. 909–917.
23. Zaheer S., Beg M., Rizvi I. et al. Correlation between serum neuron specific enolase and functional neurological outcome in patients of acute ischemic stroke. Annals of Indian Academy of Neurology, 2013, vol. 14 (4), pp. 504–508.
24. Grishanova T.G., Vavin G.V., Grigor’ev E.V. et al. Features of changes in the concentration of neuron-specific proteins in patients with severe injuries. Meditsina v Kuzbasse, 2011, vol. 10, no. 4, pp. 21–26 (in Russ.).
25. Gradisek P., Osredkar J., Korsic M., Kremzar B. Multiple indicators model of long-term mortality in traumatic brain injury. Brain Injury, 2012, vol. 12 (26), pp. 1472–1481.